Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 3 IDRX-42 versus sunitinib after imatinib failure in metastatic or unresectable GIST
NL-OMON61541Phase 3Recruiting
- Sponsor
- GSK
- Start
- Mar 2026
- Modality
- Small Molecules, Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Allosteric Modulators → Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised trial in gastrointestinal stromal tumor (GIST) comparing IDRX-42 with sunitinib (2 arms). Primary endpoint: Progression-Free Survival (PFS) per blinded independent central review. Started Mar 2026; status: recruiting.
02
Drugs
IDRX-42sunitinib
03
Conditions
gastrointestinal stromal tumor (GIST)
Beyond the preview
Go deeper on NL-OMON61541.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON61541.